3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
CNS
2
Genitourinary
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
4
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
5
Temozolomide
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
3-Iodobenzylguanidine
4
anlotinib
3
Everolimus
3
olaparib
2
cabozantinib
2
belzutifan
2
Sunitinib
2
Phenoxybenzamine
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
Axitinib
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
lanreotide
1
guadecitabine
1
fludarabine phosphate
1
copper dotatate CU-64
1
cixutumumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Paraganglioma
×
belzutifan
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled